pH-sensitive nanoparticles for colonic delivery of curcumin in inflammatory bowel disease
- PMID: 25014369
- DOI: 10.1016/j.ijpharm.2014.07.009
pH-sensitive nanoparticles for colonic delivery of curcumin in inflammatory bowel disease
Abstract
Nano-scaled particles have been found to preferentially accumulate in inflamed regions. Local delivery of anti-inflammatory drugs loaded in nanoparticles to the inflamed colonic site is of great interest for inflammatory bowel disease (IBD) treatment. Curcumin (CC) is an anti-inflammatory local agent, which presents poor ADME properties. Hence, we evaluated, both in vitro and in vivo, the local delivery of CC using pH-sensitive polymeric nanoparticles (NPs) combining both poly(lactide-co-glycolide) acid (PLGA) and a polymethacrylate polymer (Eudragit(®) S100). CC-NPs significantly enhanced CC permeation across Caco-2 cell monolayers when compared to CC in suspension. CC-NPs significantly reduced TNF-α secretion by LPS-activated macrophages (J774 cells). In vivo, CC-NPs significantly decreased neutrophil infiltration and TNF-α secretion while maintaining the colonic structure similar to the control group in a murine DSS-induced colitis model. Our results support the use of nanoparticles made of PLGA and Eudragit(®) S100 combination for CC delivery in IBD treatment.
Keywords: Curcumin; Eudragit(®); Inflammatory bowel disease; Nanoparticles; PLGA; pH-sensitive.
Copyright © 2014 Elsevier B.V. All rights reserved.
Similar articles
-
A comparative study of curcumin-loaded lipid-based nanocarriers in the treatment of inflammatory bowel disease.Colloids Surf B Biointerfaces. 2016 Jul 1;143:327-335. doi: 10.1016/j.colsurfb.2016.03.038. Epub 2016 Mar 16. Colloids Surf B Biointerfaces. 2016. PMID: 27022873
-
Drug delivery to inflamed colon by nanoparticles: comparison of different strategies.Int J Pharm. 2013 Jan 2;440(1):3-12. doi: 10.1016/j.ijpharm.2012.07.017. Epub 2012 Jul 20. Int J Pharm. 2013. PMID: 22820482
-
Budesonide-loaded nanostructured lipid carriers reduce inflammation in murine DSS-induced colitis.Int J Pharm. 2013 Oct 1;454(2):775-83. doi: 10.1016/j.ijpharm.2013.05.017. Epub 2013 May 18. Int J Pharm. 2013. PMID: 23694806
-
Curcumin as potential therapeutic natural product: a nanobiotechnological perspective.J Pharm Pharmacol. 2016 Dec;68(12):1481-1500. doi: 10.1111/jphp.12611. Epub 2016 Oct 17. J Pharm Pharmacol. 2016. PMID: 27747859 Review.
-
Advances in orally-delivered pH-sensitive nanocarrier systems; an optimistic approach for the treatment of inflammatory bowel disease.Int J Pharm. 2019 Mar 10;558:201-214. doi: 10.1016/j.ijpharm.2018.12.074. Epub 2019 Jan 4. Int J Pharm. 2019. PMID: 30615925 Review.
Cited by
-
The theranostic potentialities of bioavailable nanocurcumin in oral cancer management.BMC Complement Med Ther. 2022 Nov 24;22(1):309. doi: 10.1186/s12906-022-03770-3. BMC Complement Med Ther. 2022. PMID: 36424593 Free PMC article.
-
Oral Delivery of Biologics in Inflammatory Bowel Disease Treatment.Front Bioeng Biotechnol. 2021 Jun 3;9:675194. doi: 10.3389/fbioe.2021.675194. eCollection 2021. Front Bioeng Biotechnol. 2021. PMID: 34150733 Free PMC article. Review.
-
Advancing Gastrointestinal Health: Curcumin's Efficacy and Nanopreparations.Molecules. 2024 Apr 7;29(7):1659. doi: 10.3390/molecules29071659. Molecules. 2024. PMID: 38611938 Free PMC article. Review.
-
Complementary and Alternative Medicine Strategies for Therapeutic Gut Microbiota Modulation in Inflammatory Bowel Disease and their Next-Generation Approaches.Gastroenterol Clin North Am. 2017 Dec;46(4):689-729. doi: 10.1016/j.gtc.2017.08.002. Gastroenterol Clin North Am. 2017. PMID: 29173517 Free PMC article. Review.
-
Nanoparticle-Based Oral Drug Delivery Systems Targeting the Colon for Treatment of Ulcerative Colitis.Inflamm Bowel Dis. 2018 Jun 8;24(7):1401-1415. doi: 10.1093/ibd/izy123. Inflamm Bowel Dis. 2018. PMID: 29788186 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources